U.S. pharma giant copyright scrapped two experimental weight loss tablets previous calendar year—a after-every day pill, lotiglipron, on account of elevated liver enzymes along with a twice-everyday pill, danuglipron, as a consequence of potent Unwanted effects—but CEO Albert Bourla has mentioned the company is set to “Enjoy and gain” durin